Document is current
Any future updates will be listed below
-
Authors
Gay, Cynthia L.
Kuruc, Joann D.
Falcinelli, Shane D. https://orcid.org/0000-0002-3554-226X
Warren, Joanna A.
Reifeis, Sarah A.
Kirchherr, Jennifer L.
James, Katherine S.
Dewey, Morgan G.
Helms, Alyson
Allard, Brigitte
Stuelke, Erin
Gamble, Alicia
Plachco, Ana
Gorelick, Robert J.
Eron, Joseph J.
Hudgens, Michael
Garrido, Carolina
Goonetilleke, Nilu
DeBenedette, Mark A.
Tcherepanova, Irina Y.
Nicolette, Charles A.
Archin, Nancie M.
Margolis, David M. https://orcid.org/0000-0001-5714-0002
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI 126619, AI50410, HSN261200800001E)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (TR 002489)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 11 July 2019
Accepted: 3 March 2020
First Online: 20 March 2020
Competing interests
: J.J. Eron reports grants from Merck during the conduct of the study, personal fees from Merck, and personal fees from Gilead outside the submitted work. D.M. Margolis reports grants from N.I.H. during the conduct of the study, personal fees from Merck, and holds common stock in Gilead. C.L. Gay reports research grants from Viiv and Gilead during the conduct of this study. C.N. Nicolette, M. DeBenedette, I.Y. Tcherepanova, A. Gamble and A. Plachco were all fulltime employees of Argos Therapeutics at the time of the study.
